BACKGROUND: Based on the results of the SPIRITS trial, combination chemotherapy of S-1 plus cisplatin (SP) is now considered the standard treatment for patients with advanced gastric cancer (AGC) in Japan. On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC. METHODS: We retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC. RESULTS: From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period. The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p = 0.62). There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p = 0.91) and overall survival (median 13.8 vs. 13.5 months; p = 0.97) between the SP and XP groups. The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups. Although grade 1 or 2 hand-foot syndrome was more common in the XP group, no patients experienced grade 3 or more. CONCLUSIONS: Although the retrospective nature of this study and the small number of patients is a major limitation, SP and XP were associated with similar efficacy and safety in patients with AGC.
BACKGROUND: Based on the results of the SPIRITS trial, combination chemotherapy of S-1 plus cisplatin (SP) is now considered the standard treatment for patients with advanced gastric cancer (AGC) in Japan. On the other hand, several non-Japanese studies have shown the efficacy of capecitabine plus cisplatin (XP), which has been used as the reference arm in recent global studies of AGC. METHODS: We retrospectively compared the efficacy and safety of SP and XP in first-line treatment for patients with AGC. RESULTS: From August 2006 to November 2008, 26 AGC patients received XP in the context of 2 global trials (AVAGAST and ToGA), and 50 patients received SP during the same period. The objective response rate was 43.2 % in the SP group and 50 % in the XP group, with no significant difference (p = 0.62). There were also no significant differences in progression-free survival (median 5.8 vs. 5.2 months; p = 0.91) and overall survival (median 13.8 vs. 13.5 months; p = 0.97) between the SP and XP groups. The frequencies of hematological toxicities of grade 3 or more and non-hematological toxicities were not significantly different between the 2 groups. Although grade 1 or 2 hand-foot syndrome was more common in the XP group, no patients experienced grade 3 or more. CONCLUSIONS: Although the retrospective nature of this study and the small number of patients is a major limitation, SP and XP were associated with similar efficacy and safety in patients with AGC.
Authors: Neal J Meropol; Philip J Gold; Robert B Diasio; Michael Andria; Mandeep Dhami; Thomas Godfrey; Albert J Kovatich; Kirk A Lund; Edith Mitchell; Roland Schwarting Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: D Salonga; K D Danenberg; M Johnson; R Metzger; S Groshen; D D Tsao-Wei; H J Lenz; C G Leichman; L Leichman; R B Diasio; P V Danenberg Journal: Clin Cancer Res Date: 2000-04 Impact factor: 12.531
Authors: Eric Van Cutsem; Vladimir M Moiseyenko; Sergei Tjulandin; Alejandro Majlis; Manuel Constenla; Corrado Boni; Adriano Rodrigues; Miguel Fodor; Yee Chao; Edouard Voznyi; Marie-Laure Risse; Jaffer A Ajani Journal: J Clin Oncol Date: 2006-11-01 Impact factor: 44.544
Authors: David Cunningham; Naureen Starling; Sheela Rao; Timothy Iveson; Marianne Nicolson; Fareeda Coxon; Gary Middleton; Francis Daniel; Jacqueline Oates; Andrew Richard Norman Journal: N Engl J Med Date: 2008-01-03 Impact factor: 91.245
Authors: J-L Lee; Y-K Kang; H J Kang; K-H Lee; D Y Zang; B-Y Ryoo; J G Kim; S R Park; W K Kang; D B Shin; M-H Ryu; H M Chang; T-W Kim; J H Baek; Y J Min Journal: Br J Cancer Date: 2008-07-29 Impact factor: 7.640
Authors: Seung Tae Kim; Yong Sang Hong; Ho Yeong Lim; Jeeyun Lee; Tae Won Kim; Kyu-Pyo Kim; Sun Young Kim; Ji Yeon Baek; Jee Hyun Kim; Keun-Wook Lee; Ik-Joo Chung; Sang-Hee Cho; Kyung Hee Lee; Sang Joon Shin; Hye Jin Kang; Dong Bok Shin; Jae Won Lee; Sook Jung Jo; Young Suk Park Journal: BMC Cancer Date: 2014-11-26 Impact factor: 4.430